Keith Callahan, MD
Family Medicine · Warwick, RINPI 1629063219
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 211 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,043 and has fallen 56.8% since, to $451 in 2025.
Across 211 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$805
- Boehringer Ingelheim$614
- Pfizer$438
- AstraZeneca$404
- Johnson & Johnson$354
- GSK$333
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,323100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $805 |
| Boehringer Ingelheim | 27 | $614 |
| Pfizer | 20 | $438 |
| AstraZeneca | 22 | $404 |
| Johnson & Johnson | 19 | $354 |
| GSK | 17 | $333 |
| Lilly USA, LLC | 14 | $260 |
| AbbVie | 7 | $160 |
| Exact Sciences | 6 | $146 |
| Bayer | 4 | $82 |
| Amgen | 1 | $67 |
| Mylan Specialty L.p. | 3 | $62 |
| Regeneron Healthcare Solutions, Inc. | 3 | $62 |
| Verona Pharma, Inc. | 2 | $61 |
| Abbott | 3 | $54 |
| Amarin Pharma, Inc. | 3 | $51 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| Biohaven Pharmaceuticals, Inc. | 2 | $40 |
| Lundbeck LLC | 2 | $40 |
| Astellas Pharma US Inc | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Merck | 2 | $29 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$4,343 in reported general payments places this provider in the 85th percentile of 222 family medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 18 | $26,775 |
| XareltoRivaroxaban | 20 | $21,914 |
| JanuviaSitagliptin Phosphate | 26 | $20,808 |
| JardianceEmpagliflozin | 18 | $19,146 |
| EliquisApixaban | 23 | $17,007 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $16,453 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $13,346 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $7,964 |
| Atorvastatin Calcium | 534 | $6,983 |
| Spiriva HandihalerTiotropium Bromide | 12 | $5,809 |
| Amlodipine Besylate | 437 | $3,391 |
| Rosuvastatin Calcium | 229 | $3,033 |
| Omeprazole | 180 | $3,029 |
| Levothyroxine Sodium | 230 | $2,866 |
| SynthroidLevothyroxine Sodium | 39 | $2,855 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $805 | $26,77518 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $333 | $24,41740 claims |
| Johnson & JohnsonXarelto | $354 | $21,91420 claims |
| MerckJanuvia | $29 | $20,80826 claims |
| Boehringer IngelheimJardiance | $614 | $19,14618 claims |
| PfizerEliquis | $438 | $17,00723 claims |
| AbbVieSynthroid | $160 | $2,85539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 222 family medicine providers in Rhode Island.
Other family medicine in Warwick
- John HoranWarwick$9K
- Michael RekasWarwick$8K
- Gregory SteinmetzWarwick$8K
- Martin KerzerWarwick$7K
- Chad LamendolaWarwick$4K
- Tej BansalWarwick$4K
- Kethelyne BeauvaisWarwick$3K
- Joseph GrandeWarwick$3K
- Pierre CaronWarwick$1K
- Patrick MalloyWarwick$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.